ERBB2 and cancer: However, although the combination of trastuzumab with pertuzumab produced synergetic effects in treating HER2-overexpressing cancer cells, not all patients with HER2-overexpressing cancers benefited from trastuzumab plus pertuzumab combination therapy [9,16].